"Trimetrexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Descriptor ID |
D016597
|
| MeSH Number(s) |
D03.633.100.786.925
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Trimetrexate".
Below are MeSH descriptors whose meaning is more specific than "Trimetrexate".
This graph shows the total number of publications written about "Trimetrexate" by people in this website by year, and whether "Trimetrexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trimetrexate" by people in Profiles.
-
Fryar-Tita EB, Das JR, Davis JH, Desoto JA, Green S, Southerland WM, Bowen D. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Anticancer Res. 2007 May-Jun; 27(3B):1393-9.
-
Das JR, Fryar EB, Green S, Southerland WM, Bowen D. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate. Anticancer Res. 2006 Nov-Dec; 26(6B):4279-86.